Recruiting
Phase 1

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Sponsor:

Astellas Pharma Global Development, Inc.

Code:

NCT05014139

Conditions

Urinary Bladder Neoplasms

Carcinoma in Situ

Carcinoma Transitional Cell

Non-muscle Invasive Bladder Cancer

NMIBC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Enfortumab vedotin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information